Canine Adenovirus Type 2 (CAV-2) Vaccine

Creative Biolabs is a forward-looking research institute as well as a leading custom service provider in the field of viral vaccine development. Equipped with a team of professional scientists, we are capable of providing our clients with a variety of customized services in viral vaccine development for canine adenovirus type 2 (CAV-2). We guarantee the finest results for our customers all over the world.

Canine adenovirus type 2 (CAV-2) is a member of the adenoviridae virus family. CAV-2 leads to recessive or mild respiratory tract infection and may cause infectious laryngotracheitis and symptoms of pneumonia. The clinical features show persistent high fever, cough, serous to mucous nasal leakage, tonsillitis, laryngotracheitis and pneumonia and other respiratory symptoms. It often shows the highest morbidity and mortality rates in puppies less than half a year. CAV-2 can cause a cough in an entire population. CAV-2 is mainly transmitted through direct (nasal to nasal) and indirect contact with the nasal secretions of infected dogs. The virus replicates in ciliated bronchial epithelial cells, surface cells of the nasal mucosa, pharynx and tonsil recesses, mucosa of the bronchi, and alveolar type 2 epithelial cells. It can also replicate in the posterior pharynx lymph nodes and bronchial lymph nodes.

Fig.1 The model of adenovirus.

The Joint Vaccine

Joint vaccine is a core vaccine that contains live attenuated canine distemper virus, canine adenovirus (CAV-2), canine parvovirus (C154) and canine parainfluenza virus. Joint vaccine is a commonly used dog vaccine. It prevents canine distemper, hepatitis and parvovirus. It is provided as a freeze-dried powder in a single-use bottle and needs be diluted to further provide protection against leptospirosis. A single injection of this vaccine is sufficient to provide good immunity at any time after 10 weeks for most dogs. If the risk is considered significant, the vaccine can be administered as early as possible, but it must be administered after 10 weeks of age. In dogs, especially very large breeds, vaccination after 16 weeks is more likely to provide sufficient protection due to maternal immunization interference vaccines.

The Recombinant Attenuated Vaccine for CAV-2

CAV-2 is considered to be one of the causes of respiratory infections. Infectious tracheal bronchitis (dog cough) is an acute inflammation of the upper respiratory tract that can develop into deadly pneumonia in puppies, or chronic bronchitis in elderly dogs. The disease is highly contagious and spreads rapidly between dogs when kept together. Canine adenovirus type 2 has been used in many attenuated vaccine developments, the data indicates that CAV-2 is a particularly interesting target to study the pathophysiology and potential treatment of neurodegenerative diseases, as anti-tumoral and anti-viral vaccines, tracer of synaptic junctions, oncolytic virus.

Our Services for CAV-2 Viral Vaccines

Our CAV-2 viral vaccines platform, include in-depth discovery chemistry and biology, aims to offer streamlined development services from vaccine target identification to safety and toxicity studies. We have integrated high-quality viral services based in America and span the entire development chain from discovery to commercialization. Our laboratory services have many advanced chemical and biological technologies to support customer’s needs in the fast-growing viral vaccines development.

One-stop vaccine manufacturing service

Multiple and well-established vaccine development assay

An efficient and cost-effective process

Creative Biolabs is pleased to share our cutting-edge technology and extensive expertise in the field of viral vaccine development and has focused on the canine adenovirus type 2 vaccines for years. We can offer high-quality customized services by adjusting protocols to meet even the most specific requirements. If you are interested in our services, please contact us for more details.